Table 3 Patient characteristics and treatment in small and large tumors
GTV diameter N (%) | ||||
|---|---|---|---|---|
0–5 cm | 5 cm< | P value | ||
N (%) | 50 (39.1) | 78 (60.9) | ||
Age (mean ± SD, years) | 63.61 ± 9.11 | 64.72 ± 9.27 | 0.506 | |
Gender male | 39 (78.0) | 66 (84.6) | 0.342 | |
ECOG | 0 | 26 (53.1) | 37 (48.1) | 0.460 |
1 | 17 (34.7) | 34 (44.2) | ||
2 | 6 (12.2) | 5 (6.5) | ||
3 | 0 (0) | 1 (1.3) | ||
Child-Pugh Group | A | 31 (64.6) | 50 (67.6) | 0.271 |
B | 11 (22.9) | 23 (31.3) | ||
C | 6 (12.5) | 1 (1.4) | ||
ALBI grade | 1 | 7 (19.0) | 16 (28.6) | 0.096 |
2 | 18 (50.0) | 33 (58.9) | ||
3 | 11 (30.6) | 7 (12.5) | ||
Received prior local therapy | 38 (76.0) | 56 (71.8) | 0.599 | |
Dose per fraction | Conventional (180–200 cGy/Fx) | 3 (6.0) | 4 (5.1) | < 0.001 |
Hypofractionated (201–500 cGy/Fx) | 11 (22.0) | 68 (87.2) | ||
Ultrafractionated (501 cGy/Fx≤) | 36 72.0 | 6 (7.7) | ||
Number of fractions | 1–5 | 36 (72.0) | 6 (7.7) | < 0.001 |
6–20 | 8 (16.0) | 29 (37.2) | ||
> 20 | 6 (12.0) | 43 (55.1) | ||
Planned treatment break | 13 (26.0) | 21 (26. 9) | 0.908 | |
RT treatment modality | Proton | 4 (8.0) | 32 (41.0) | < 0.001 |
GTV volume (median, Q1, Q3 cm³) | 24, 13, 43 | 314, 173, 538 | < 0.001 | |
GTV equivalent sphere diameter (median, Q1, Q3 cm) | 3.5, 2.9, 4.3 | 8.4, 6.9, 10.0 | < 0.001 | |
BED10 (median, Q1, Q3, Gy) | 100, 95, 100 | 69, 69, 78 | < 0.001 | |
Follow-up (median, months) | 16.3 | 14.8 | 0.394 | |